Slide 1

PATIENT TRIALS

Slide 1
Slide 1

PATIENT TRIALS

Slide 1
previous arrowprevious arrow
next arrownext arrow

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE
Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

Check out the study “Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects”

Scientific News

Thieme: Diabetes mellitus und Herz

Scientific News

Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults

Science

Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Science
CRO Leadership Awards 2019

CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability.

European Biotechnology Guide

Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019.

EcoVadis – CSR Rating

Based on the CSR rating by EcoVadis in 2022 CRS has been granted Silver Recognition Level.